Hjem › Lungekreft › Oklahoma › Oklahoma City
Kliniske studier for Lungekreft i Oklahoma City, OK
19 studier for Lungekreft søker deltakere på steder i og rundt Oklahoma City (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
The Vanguard Study: Testing a New Way to Screen for Cancer
RekruttererFrivillige helsepersonell ønskes velkommen
- University of Oklahoma Health Sciences Center, Oklahoma City
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial
RekruttererFase 3
- Mercy Hospital Oklahoma City, Oklahoma City
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Cancer Institute of Oklahoma, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Mercy Hospital Oklahoma City, Oklahoma City
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
RekruttererFase 3
- Hightower Clinical, LLC ( Site 0084), Oklahoma City
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
RekruttererFase 2/3
- INTEGRIS Cancer Institute of Oklahoma, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RekruttererFase 1/2
- University of Oklahoma, Oklahoma City
Identification and Validation of Blood-Based Biomarkers for Early Detection of Asymptomatic Lung Cancer in High-Risk Heavy Smokers
RekruttererObservasjonsstudieFrivillige helsepersonell ønskes velkommen
- Site 101, Oklahoma City
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekruttererFase 3
- University of Oklahoma Health Sciences Center, Oklahoma City
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
RekruttererFase 1
- Xencor Investigative Site, Oklahoma City
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
RekruttererFase 1/2
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2/3
- University of Oklahoma Health Sciences Center, Oklahoma City
- Integris Southwest Medical Center, Oklahoma City
- Mercy Hospital Oklahoma City, Oklahoma City
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
RekruttererFase 2
- University of Oklahoma Health Sciences Center, Oklahoma City
Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening
RekruttererObservasjonsstudie
- Hightower Clinical, Oklahoma City
Lungekreft-studier i andre byer
- Houston, TX78 studier
- Boston, MA62 studier
- New York City, NY60 studier
- Los Angeles, CA45 studier
- Arlington, VA41 studier
- Washington, DC41 studier
- Chicago, IL41 studier
- Baltimore, MD40 studier
- Nashville, TN40 studier
- St. Louis, MO39 studier
- Columbus, OH37 studier
- Philadelphia, PA36 studier
Andre studier i Oklahoma City
- Ikke-småcellet lungekreft28 studier
- Eggstokkreft28 studier
- Endometriekreft25 studier
- Kolorektal kreft22 studier
- Prostatakreft21 studier
- Brystkreft17 studier
- Metastatisk kreft16 studier
- Kreft (alle typer)14 studier
- Akut myelogen leukemi14 studier
- Plateepitelcancer i hode og hals13 studier
- Blærekreft11 studier
- Pankreaskreft11 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.